Format

Send to

Choose Destination
Breast Cancer Res Treat. 2009 May;115(2):359-63. doi: 10.1007/s10549-008-0128-9. Epub 2008 Jul 23.

Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.

Author information

1
Pomeranian Medical University, Szczecin, Poland.

Abstract

BACKGROUND:

Ten patients with breast cancer and a breast cancer susceptibility gene 1 (BRCA1) mutation, who presented with stages I to III breast cancer between December 2006 and 2007, were treated with four cycles of neoadjuvant cisplatin, followed by mastectomy and conventional chemotherapy.

METHODS:

The excised breast tissue and lymph nodes were examined for the presence of residual disease.

RESULTS:

Pathologic complete response was observed in nine patients (90%).

CONCLUSIONS:

Platinum-based chemotherapy appears to be effective in a high proportion of patients with BRCA1-associated breast cancers. Clinical trials are now warranted to determine the optimum treatment for this subgroup of breast cancer patients.

PMID:
18649131
DOI:
10.1007/s10549-008-0128-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center